Posted by Michael Wonder on 22 Jan 2025
Bluejay Therapeutics receives US FDA breakthrough therapy designation for brelovitug (BJT-778) for the treatment of chronic hepatitis delta
21 January 2025 - Bluejay Therapeutics today announced that its lead product candidate brelovitug (also known as BJT-778) has received US FDA breakthrough therapy designation for the treatment of chronic hepatitis delta.
There are currently no approved treatments for chronic hepatitis D in the US and most countries around the world.
